A safe and effective painkiller, is that possible? Yes it is, it’s called palmitoylethanolamide (or N-(2-Hydroxyethyl)hexadecanamide) and it’s produced by our own body. Palmitoylethanolamide is available in its most pure form as a supplement called PeaCure.

Palmitoylethanolamide (PEA), a bodily fatty acid amine that is available as a supplement, keeps amazing. The substance has earned its status in all types of pain syndromes and. In May 2012 a randomized double-blinded study also revealed positive results towards jaw pain due to arthritis in the jaw, also called arthritis of the temporomandibular joint.

The study proved that this bodily substance is effective and safe. The latter being of specific importance as most other pain medicine is not! Therefore PEA can be called a good and safe pain relief remedy for valid reasons. We quote the authors:

… these results are of particular interest since they confirm the total lack of side effects ascribed to the use of PEA, as demonstrated by clinical studies conducted on a great number of young as well as older adult subjects …

 

Palmitoylethanolamide against jaw pain and acute pain after pulling a tooth

A few months before, jaw surgeons had already pointed out that palmitoylethanolamide can also be useful for pain after pulling wisdom teeth. [1]

So now there is a publication about the value of palmitoylethanolamide (PEA) for jaw pain in English language. Not only does the substance work well against jaw pain, the jaw’s ability to open also improved. [2]

More and more scientific publications about the value of this bodily substance are becoming available, and doctors can no longer ignore the facts. In this new study, PEA, with no notable side effects, also turned out to be superior to conventional medicine, which cause gastrointestinal bleeding and can cause death.

Palmitoylethanolamide: safe and effective and a better alternative than regular pain medicine of the NSAID category

The authors emphasized that:

  1. PEA is a body’s own substance that protects tissue
  2. PEA has not notable side effects and can be used over a prolonged period of time
  3. PEA is important in treating chronic pain
  4. PEA has a double therapeutic effect. It works as a pain relief and it is anti-inflammatory.
  5. PEA is an important alternative for the commonly used aspirin-like painkillers (NSAID’s)

The table below clearly shows that PEA was more successful in reducing pain than the painkiller Ibuprofen!

And now the conclusion:

The endogenous nature of PEA and its capacity to act locally and to protect tissues against damage are the premises upon which its therapeutic applications are based:

First, the lack of side effects allows the therapeutic use of PEA for long periods, and this is particularly important for patients manifesting pain associated with chronic diseases and who are already undergoing several debilitating pharmacological therapies.

Secondly, the presence of a double therapeutic effect, anti-inflammatory and antinociceptive, is particularly important for pathologies presenting chronic inflammatory processes such as TMJ or joint OA that continuously stimulate the somatosensory system and induce allodynia and hyperalgesia.

In conclusion, the results of the present study demonstrate that PEA is effective in reducing TMD-related OA and arthralgia pain, thus suggesting its therapeutic use as an alternative tool to ibuprofen.  

PEA keeps surprising and is a breakthrough in medicine. In 2012 alone, PEA’s effect became apparent in a number of animal tests, as well as clinical reports, for a plethora of different symptoms that involve pain and inflammation. [3] [4] [5] [6] [7]  [8][9]

 

References

[1] Bacci C, Cassetta G, Emanuele B, Berengo M. | Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. | ISRN Surg. | 2011;2011:917350. doi: 10.5402/2011/917350. Epub 2011 Apr 17.

[2] Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. | Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. | J Orofac Pain. | 2012 Spring;26(2):99-104.

[3] Kumar A, Qiao Z, Kumar P, Song ZH. | Effects of palmitoylethanolamide on aqueous humor outflow. | Invest Ophthalmol Vis Sci. | 2012 Jul 3;53(8):4416-25. doi: 10.1167/iovs.11-9294.

[4] Skaper SD. | Conference report: 1st workshop on “palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator”. | CNS Neurol Disord Drug Targets. | 2012 May;11(3):191.

[5] D’Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. |Palmitoylethanolamide protects against the amyloid-?25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. |Neuropsychopharmacology. | 2012 Jun;37(7):1784-92. doi: 10.1038/npp.2012.25. Epub 2012 Mar 14.

[6] Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L. |Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-?. | J Neuroinflammation. | 2012 Mar 9;9:49. doi: 10.1186/1742-2094-9-21.

[7] Redlich S, Ribes S, Schütze S, Czesnik D, Nau R. | Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. | J Neuroimmunol. | 2012 Mar;244(1-2):32-4. doi: 10.1016/j.jneuroim.2011.12.013. Epub 2012 Jan 12.

[8] Naderi N, Majidi M, Mousavi Z, Khoramian Tusi S, Mansouri Z, Khodagholi F. | The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-? expression in rats. |Neurochem Res. | 2012 Apr;37(4):778-85. doi: 10.1007/s11064-011-0672-2. Epub 2011 Dec 27.

[9] de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, Marabese I, D’Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S. | Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. | Eur J Pharmacol. | 2012 Feb 15;676(1-3):41-50. doi: 10.1016/j.ejphar.2011.11.034. Epub 2011 Dec 3.